Benzbromaron

Benzbromaron, gut tedavisinde, özellikle birinci basamak tedavi olan allopurinol başarısız olduğunda veya dayanılmaz yan etkiler ürettiğinde kullanılan, ürikozürik bir ajan ve ksantin oksidaz^[1] inhibitörüdür. Yapısal olarak antiaritmik amiodaron ile ilişkilidir.^[2]

Benzbromaron oldukça etkilidir ve iyi tolere edilir.^[3]^[4]^[5]^[6]

Kaynakça

^ "The pharmacology of hypouricemic effect of benzbromarone". The Journal of Rheumatology. 2 (4): 437-45. December 1975. PMID 1206675.
^ "Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles". Drug Metabolism and Disposition. 34 (10): 1688-96. October 2006. doi:10.1124/dmd.106.010678. PMID 16815961.
^ "Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia". Drugs. 14 (5): 349-66. November 1977. doi:10.2165/00003495-197714050-00002. PMID 338280.
^ "Ten years' experience with benzbromarone in the management of gout and hyperuricaemia" (PDF). South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde. 59 (20): 701-6. May 1981. PMID 7221794. 4 Kasım 2021 tarihinde kaynağından arşivlendi (PDF). Erişim tarihi: 30 Aralık 2022.
^ "Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout". Annals of the Rheumatic Diseases. 57 (9): 545-9. September 1998. doi:10.1136/ard.57.9.545. PMC 1752740 $2. PMID 9849314.
^ "Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients". Clinical Rheumatology. 26 (9): 1459-65. September 2007. doi:10.1007/s10067-006-0528-3. PMID 17308859.